Myeloperoxidase and free iron levels

Potential biomarkers for early detection and prognosis of ovarian cancer

Nicole M. Fletcher, Zhongliang Jiang, Rouba Ali-Fehmi, Nancy K. Levin, Jimmy Belotte, Michael A. Tainsky, Michael Peter Diamond, Husam M. Abu-Soud, Ghassan M. Saed

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer. Methods: Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant). Results: There was a significant increase in the level of free iron in serum and tissues obtained from stages II-IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups. Conclusions: Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalCancer Biomarkers
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Peroxidase
Iron
Biomarkers
Serum
Inflammation
Analysis of Variance
Enzyme-Linked Immunosorbent Assay

Keywords

  • Myeloperoxidase
  • biomarkers
  • free iron
  • ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Fletcher, N. M., Jiang, Z., Ali-Fehmi, R., Levin, N. K., Belotte, J., Tainsky, M. A., ... Saed, G. M. (2011). Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer. Cancer Biomarkers, 10(6), 267-275. https://doi.org/10.3233/CBM-2012-0255

Myeloperoxidase and free iron levels : Potential biomarkers for early detection and prognosis of ovarian cancer. / Fletcher, Nicole M.; Jiang, Zhongliang; Ali-Fehmi, Rouba; Levin, Nancy K.; Belotte, Jimmy; Tainsky, Michael A.; Diamond, Michael Peter; Abu-Soud, Husam M.; Saed, Ghassan M.

In: Cancer Biomarkers, Vol. 10, No. 6, 01.12.2011, p. 267-275.

Research output: Contribution to journalArticle

Fletcher, NM, Jiang, Z, Ali-Fehmi, R, Levin, NK, Belotte, J, Tainsky, MA, Diamond, MP, Abu-Soud, HM & Saed, GM 2011, 'Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer', Cancer Biomarkers, vol. 10, no. 6, pp. 267-275. https://doi.org/10.3233/CBM-2012-0255
Fletcher, Nicole M. ; Jiang, Zhongliang ; Ali-Fehmi, Rouba ; Levin, Nancy K. ; Belotte, Jimmy ; Tainsky, Michael A. ; Diamond, Michael Peter ; Abu-Soud, Husam M. ; Saed, Ghassan M. / Myeloperoxidase and free iron levels : Potential biomarkers for early detection and prognosis of ovarian cancer. In: Cancer Biomarkers. 2011 ; Vol. 10, No. 6. pp. 267-275.
@article{001bea64b00d428ea17d3d29fbddda84,
title = "Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer",
abstract = "Objective: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer. Methods: Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant). Results: There was a significant increase in the level of free iron in serum and tissues obtained from stages II-IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups. Conclusions: Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.",
keywords = "Myeloperoxidase, biomarkers, free iron, ovarian cancer",
author = "Fletcher, {Nicole M.} and Zhongliang Jiang and Rouba Ali-Fehmi and Levin, {Nancy K.} and Jimmy Belotte and Tainsky, {Michael A.} and Diamond, {Michael Peter} and Abu-Soud, {Husam M.} and Saed, {Ghassan M.}",
year = "2011",
month = "12",
day = "1",
doi = "10.3233/CBM-2012-0255",
language = "English (US)",
volume = "10",
pages = "267--275",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "6",

}

TY - JOUR

T1 - Myeloperoxidase and free iron levels

T2 - Potential biomarkers for early detection and prognosis of ovarian cancer

AU - Fletcher, Nicole M.

AU - Jiang, Zhongliang

AU - Ali-Fehmi, Rouba

AU - Levin, Nancy K.

AU - Belotte, Jimmy

AU - Tainsky, Michael A.

AU - Diamond, Michael Peter

AU - Abu-Soud, Husam M.

AU - Saed, Ghassan M.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer. Methods: Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant). Results: There was a significant increase in the level of free iron in serum and tissues obtained from stages II-IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups. Conclusions: Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.

AB - Objective: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer. Methods: Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant). Results: There was a significant increase in the level of free iron in serum and tissues obtained from stages II-IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups. Conclusions: Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.

KW - Myeloperoxidase

KW - biomarkers

KW - free iron

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84864445472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864445472&partnerID=8YFLogxK

U2 - 10.3233/CBM-2012-0255

DO - 10.3233/CBM-2012-0255

M3 - Article

VL - 10

SP - 267

EP - 275

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 6

ER -